0001193125-23-141992.txt : 20230511 0001193125-23-141992.hdr.sgml : 20230511 20230511160036 ACCESSION NUMBER: 0001193125-23-141992 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230508 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 23910741 BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 BUSINESS PHONE: 9729267267 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 8-K 1 d502794d8k.htm 8-K 8-K
TEVA PHARMACEUTICAL INDUSTRIES LTD false 0000818686 0000818686 2023-05-08 2023-05-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 8, 2023

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

 

 

 

Israel   001-16174   00-0000000

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

124 Dvora Hanevi’a Street

Tel Aviv 6944020, Israel

(Address of Principal Executive Offices, including Zip Code)

+972-3-914-8213

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

American Depositary Shares, each representing one Ordinary Share   TEVA   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

ITEM 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers

On May 8, 2023, Jean-Michel Halfon informed Teva Pharmaceutical Industries Ltd. (“Teva”) that in light of personal reasons, he will resign from Teva’s Board of Directors (“Board”), effective immediately. Mr. Halfon has served as a director on the Board since 2014, as chair of the Board’s HR and Compensation Committee and more recently as chair of the Compliance Committee.

As provided in Teva’s Notice of 2023 Annual Meeting of Shareholders and Proxy Statement, filed with the Securities and Exchange Commission on April 19, 2023, Mr. Halfon is not standing for re-election at Teva’s upcoming annual meeting of shareholders on June 15, 2023.

Mr. Halfon’s decision to resign as a director was not due to any disagreements with Teva.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: May 11, 2023     By:  

/s/ Eli Kalif

      Name:   Eli Kalif
      Title:   Executive Vice President, Chief Financial Officer
 EX-101.SCH 2 teva-20230508.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 teva-20230508_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 teva-20230508_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 08, 2023
Cover [Abstract]  
Entity Registrant Name TEVA PHARMACEUTICAL INDUSTRIES LTD
Amendment Flag false
Entity Central Index Key 0000818686
Document Type 8-K
Document Period End Date May 08, 2023
Entity Incorporation State Country Code L3
Entity File Number 001-16174
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One 124 Dvora Hanevi’a Street
Entity Address, City or Town Tel Aviv
Entity Address, Postal Zip Code 6944020
Entity Address, Country IL
City Area Code 972
Local Phone Number 3-914-8213
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title American Depositary Shares, each representing one Ordinary Share
Trading Symbol TEVA
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 6 d502794d8k_htm.xml IDEA: XBRL DOCUMENT 0000818686 2023-05-08 2023-05-08 TEVA PHARMACEUTICAL INDUSTRIES LTD false 0000818686 8-K 2023-05-08 L3 001-16174 00-0000000 124 Dvora Hanevi’a Street Tel Aviv 6944020 IL 972 3-914-8213 false false false false American Depositary Shares, each representing one Ordinary Share TEVA NYSE false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d502794d8k.htm 7 d502794d8k.htm teva-20230508.xsd teva-20230508_lab.xml teva-20230508_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d502794d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d502794d8k.htm" ] }, "labelLink": { "local": [ "teva-20230508_lab.xml" ] }, "presentationLink": { "local": [ "teva-20230508_pre.xml" ] }, "schema": { "local": [ "teva-20230508.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "teva", "nsuri": "http://www.tevapharm.com/20230508", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d502794d8k.htm", "contextRef": "duration_2023-05-08_to_2023-05-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d502794d8k.htm", "contextRef": "duration_2023-05-08_to_2023-05-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001193125-23-141992-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-141992-xbrl.zip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